한글목차

혈액 종양 검사의 동향과 예측

세계의 혈액 종양 검사 시장은 2024년부터 2030년까지의 복합 연간 성장률(CAGR) 14.5%를 나타낼 전망이며 2030년까지 추정 72억 달러에 이를 것으로 예상됩니다. 이 시장의 주요 촉진요인은 맞춤형 의료에 관한 학회 수 증가, 혈액암 이환율의 상승, 민간 진단 시설 증가입니다. 세계의 혈액 종양 검사 시장의 미래는 병원 및 학술 및 연구 기관 시장의 기회에 의해 유망시되고 있습니다.

혈액 종양 검사시장 인사이트

Lucintel의 예측은 맞춤형 약물 요법을 포함한 다양한 치료 옵션에 대한 일반 지식 증가로 인해 예측 기간 동안 서비스가 더 큰 부문을 유지합니다.

북미는 다발성 골수종, 림프종, 백혈병의 유병률 증가, 최첨단 의료 시설 및 건강 관리의 가용성, 신기술 도입으로 예측 기간 동안 최대 지역으로 계속 될 것으로 보입니다.

FAQ

Q1. 시장 규모는?

A1. 세계의 혈액 종양 검사 시장은 2030년까지 예상 72억 달러에 이를 것으로 예상됩니다.

Q2. 시장의 성장 예측은?

A2. 세계의 혈액 종양 검사 시장은 2024년부터 2030년에 걸쳐 복합 연간 성장률(CAGR) 14.5%로 성장할 것으로 예상됩니다.

Q3. 시장 성장에 영향을 미치는 주요 촉진요인은?

A3. 이 시장의 주요 촉진요인은 개별화의료에 관한 학회수 증가, 혈액암 이환율의 상승, 민간진단시설 증가입니다.

Q4. 시장의 주요 부문은?

A4. 세계의 혈액 종양 검사 시장의 미래는 병원, 학술 및 연구 기관 시장의 기회로 유망합니다.

Q5. 시장의 주요 기업은?

A5. 주요 혈액 종양 검사 회사는 다음과 같습니다.

• F. Hoffmann-La Roche
• Abbott
• EntroGen
• Qiagen
• Cepheid
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Illumina
• Amoy Diagnostics
• ArcherDX

Q6. 앞으로 가장 큰 시장 부문은?

A6. Lucintel은 맞춤형 약물 요법을 포함한 다양한 치료 옵션에 대한 일반적인 지식 증가로 인해 예측 기간 동안 서비스가 더 큰 부문을 유지할 것으로 예측됩니다.

Q7. 시장에서 향후 5년간 최대가 될 것으로 예상되는 지역은?

A7. 북미는 다발성 골수종, 림프종, 백혈병의 유병률 증가, 최첨단의 의료시설과 헬스케어의 가용성, 신기술의 인트로덕션보다 예측기간 동안에도 최대지역으로 남아 있습니다.

Q8. 보고서의 커스터마이즈는 가능?

A8. 그렇습니다, Lucintel는 추가 비용 없이 10% 주문을 받아서 만듭니다.

목차

제1장 주요 요약

제2장 세계의 혈액 종양 검사 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018-2030년)

• 거시경제 동향(2018년-2023년)과 예측(2024년-2030년)
• 세계의 혈액 종양 검사 시장 동향(2018년-2023년)과 예측(2024년-2030년)
• 기술별 세계의 혈액 종양 검사시장
  • PCR
  • IHC
  • NGS
  • 세포유전학
  • 기타
• 암유형별 세계의 혈액 종양 검사 시장
  • 백혈병
  • 림프종
  • 골수 증식성 종양
  • 기타
• 제품별 세계의 혈액 종양 검사시장
  • 분석 키트 및 시약
  • 서비스
• 최종 용도별 세계의 혈액 종양 검사 시장
  • 병원
  • 학술연구기관
  • 기타

제4장 지역별 시장 동향과 예측 분석(2018년-2023년)

• 지역별 세계의 혈액 종양 검사시장
• 북미의 혈액 종양 검사시장
• 유럽의 혈액 종양 검사시장
• 아시아태평양의 혈액 종양 검사시장
• 기타 지역의 혈액 종양 검사 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상의 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 기술에 의한 세계의 혈액 종양 검사 시장의 성장 기회
  • 암유형별 세계의 혈액 종양 검사 시장의 성장 기회
  • 제품별 세계의 혈액 종양 검사 시장의 성장 기회
  • 최종 용도별 세계의 혈액 종양 검사 시장의 성장 기회
  • 지역별 세계의 혈액 종양 검사 시장의 성장 기회
• 세계의 혈액 종양 검사 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 혈액 종양 검사 시장의 능력 확대
  • 세계의 혈액 종양 검사 시장에서의 합병, 인수, 합작 사업
  • 인증 및 라이선싱

제7장 유력 기업의 기업 프로파일

• F. Hoffmann-La Roche
• Abbott
• EntroGen
• Qiagen
• Cepheid
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Illumina
• Amoy Diagnostics
• ArcherDX

영문목차

Hemato Oncology Testing Trends and Forecast

The future of the global hemato oncology testing market looks promising with opportunities in the hospital and academic & research institutes market. The global hemato oncology testing market is expected to reach an estimated $7.2 billion by 2030 with a CAGR of 14.5% from 2024 to 2030. The major drivers for this market are increasing the number of conferences on personalized medicine, rising rate of hematologic cancer, and growing number of privately run diagnostic facilities.

A more than 150-page report is developed to help in your business decisions.

Hemato Oncology Testing by Segment

The study includes a forecast for the global hemato oncology testing by technology, cancer type, product, end use, and region.

Hemato Oncology Testing Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

• PCR
• IHC
• NGS
• Cytogenetics
• Others

Hemato Oncology Testing Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

• Leukemia
• Lymphoma
• Myeloproliferative Neoplasms
• Other

Hemato Oncology Testing Market by Product [Shipment Analysis by Value from 2018 to 2030]:

• Assay Kits and Reagents
• Services

Hemato Oncology Testing Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Academic & Research Institutes
• Others

Hemato Oncology Testing Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Hemato Oncology Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies hemato oncology testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hemato oncology testing companies profiled in this report include-

• F. Hoffmann-La Roche
• Abbott
• EntroGen
• Qiagen
• Cepheid
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Illumina
• Amoy Diagnostics
• ArcherDX

Hemato Oncology Testing Market Insights

Lucintel forecasts that service will remain the larger segment over the forecast period due to increasing public knowledge of various treatment options, including tailored medications.

North America will remain the largest region over the forecast period due to the increased prevalence of multiple myeloma, lymphoma, and leukemia, along with the availability of cutting-edge medical facilities and healthcare, as well as the introduction of new technology.

Features of the Global Hemato Oncology Testing Market

Market Size Estimates: Hemato oncology testing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Hemato oncology testing market size by various segments, such as by technology, cancer type, product, end use, and region in terms of value ($B).

Regional Analysis: Hemato oncology testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different technology, cancer type, product, end use, and regions for the hemato oncology testing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hemato oncology testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the hemato oncology testing market size?

Answer: The global hemato oncology testing market is expected to reach an estimated $7.2 billion by 2030.

Q2. What is the growth forecast for hemato oncology testing market?

Answer: The global hemato oncology testing market is expected to grow with a CAGR of 14.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the hemato oncology testing market?

Answer: The major drivers for this market are increasing the number of conferences on personalized medicine, rising rate of hematologic cancer, and growing number of privately run diagnostic facilities.

Q4. What are the major segments for hemato oncology testing market?

Answer: The future of the global hemato oncology testing market looks promising with opportunities in the hospital and academic & research institutes market.

Q5. Who are the key hemato oncology testing market companies?

Answer: Some of the key hemato oncology testing companies are as follows.

• F. Hoffmann-La Roche
• Abbott
• EntroGen
• Qiagen
• Cepheid
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Illumina
• Amoy Diagnostics
• ArcherDX

Q6. Which hemato oncology testing market segment will be the largest in future?

Answer: Lucintel forecasts that service will remain the larger segment over the forecast period due to increasing public knowledge of various treatment options, including tailored medications.

Q7. In hemato oncology testing market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the increased prevalence of multiple myeloma, lymphoma, and leukemia, along with the availability of cutting-edge medical facilities and healthcare, as well as the introduction of new technology.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the hemato oncology testing market by technology (PCR, IHC, NGS, cytogenetics, and others), cancer type (leukemia, lymphoma, myeloproliferative neoplasms, and other), product (assay kits and reagents and services), end use (hospitals, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Hemato Oncology Testing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Hemato Oncology Testing Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Hemato Oncology Testing Market by Technology
  • 3.3.1: PCR
  • 3.3.2: IHC
  • 3.3.3: NGS
  • 3.3.4: Cytogenetics
  • 3.3.5: Others
• 3.4: Global Hemato Oncology Testing Market by Cancer Type
  • 3.4.1: Leukemia
  • 3.4.2: Lymphoma
  • 3.4.3: Myeloproliferative Neoplasms
  • 3.4.4: Other
• 3.5: Global Hemato Oncology Testing Market by Product
  • 3.5.1: Assay Kits and Reagents
  • 3.5.2: Services
• 3.6: Global Hemato Oncology Testing Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Academic & Research Institutes
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Hemato Oncology Testing Market by Region
• 4.2: North American Hemato Oncology Testing Market
  • 4.2.1: North American Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
  • 4.2.2: North American Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others
• 4.3: European Hemato Oncology Testing Market
  • 4.3.1: European Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
  • 4.3.2: European Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others
• 4.4: APAC Hemato Oncology Testing Market
  • 4.4.1: APAC Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
  • 4.4.2: APAC Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others
• 4.5: ROW Hemato Oncology Testing Market
  • 4.5.1: ROW Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
  • 4.5.2: ROW Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Hemato Oncology Testing Market by Technology
  • 6.1.2: Growth Opportunities for the Global Hemato Oncology Testing Market by Cancer Type
  • 6.1.3: Growth Opportunities for the Global Hemato Oncology Testing Market by Product
  • 6.1.4: Growth Opportunities for the Global Hemato Oncology Testing Market by End Use
  • 6.1.5: Growth Opportunities for the Global Hemato Oncology Testing Market by Region
• 6.2: Emerging Trends in the Global Hemato Oncology Testing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Hemato Oncology Testing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Hemato Oncology Testing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: F. Hoffmann-La Roche
• 7.2: Abbott
• 7.3: EntroGen
• 7.4: Qiagen
• 7.5: Cepheid
• 7.6: Thermo Fisher Scientific
• 7.7: Bio-Rad Laboratories
• 7.8: Illumina
• 7.9: Amoy Diagnostics
• 7.10: ArcherDX